Efficacy of Palbociclib and Endocrine Treatment in Heavily Pretreated Hormone Receptor-positive Her2-negative Advanced Breast Cancer: Retrospective Multicenter Trial

Heavily Pretreated

Efficacy of Palbociclib and Endocrine Treatment in Heavily Pretreated Hormone Receptor-positive/HER2-negative Advanced Breast Cancer: Retrospective Multicenter Trial

Balkan Medical Journal ◽

10.4274/balkanmedj.galenos.2020.2019.11.143 ◽

2020 ◽

Vol 37 (2) ◽

pp. 104-107 ◽

Cited By ~ 1

Author(s):

Atakan Demir ◽

Nil Molinas Mandel ◽

Semra Paydas ◽

Gökhan Demir ◽

Özlem Er ◽

...

Keyword(s):

Breast Cancer ◽

Advanced Breast Cancer ◽

Hormone Receptor ◽

Multicenter Trial ◽

Advanced Breast ◽

Endocrine Treatment ◽

Heavily Pretreated

Palbociclib and endocrine therapy in heavily pretreated hormone receptor-positive HER2-negative advanced breast cancer: the UK Compassionate Access Programme experience

Breast Cancer Research and Treatment ◽

10.1007/s10549-019-05134-x ◽

2019 ◽

Vol 174 (3) ◽

pp. 731-740 ◽

Cited By ~ 3

Author(s):

Nicolò Matteo Luca Battisti ◽

Belinda Kingston ◽

Judy King ◽

Arshi Denton ◽

Simon Waters ◽

...

Keyword(s):

Breast Cancer ◽

Advanced Breast Cancer ◽

Endocrine Therapy ◽

Hormone Receptor ◽

Advanced Breast ◽

Heavily Pretreated ◽

Access Programme ◽

The Uk

Abstract OT2-01-02: Phase III study of ribociclib (LEE011) in combination with fulvestrant for the treatment of postmenopausal patients (pts) with hormone receptor-positive (HR+), HER2-negative (HER2–) advanced breast cancer (aBC) who have received no or only one line of prior endocrine treatment: MONALEESA-3

10.1158/1538-7445.sabcs15-ot2-01-02 ◽

2016 ◽

Cited By ~ 2

Author(s):

PA Fasching ◽

G Jerusalem ◽

X Pivot ◽

M Martin ◽

M De Laurentiis ◽

...

Keyword(s):

Breast Cancer ◽

Advanced Breast Cancer ◽

Hormone Receptor ◽

Advanced Breast ◽

Phase Iii ◽

Endocrine Treatment ◽

Phase Iii Study

Fulvestrant: Expanding the endocrine treatment options for patients with hormone receptor-positive advanced breast cancer

The Breast ◽

10.1016/j.breast.2007.12.004 ◽

2008 ◽

Vol 17 ◽

pp. 16-21 ◽

Cited By ~ 16

Author(s):

Stephen Chia ◽

William Gradishar

Keyword(s):

Breast Cancer ◽

Advanced Breast Cancer ◽

Hormone Receptor ◽

Treatment Options ◽

Advanced Breast ◽

Endocrine Treatment ◽

Ribociclib + letrozole for postmenopausal women with hormone receptor-positive (HR+), HER2-negative advanced breast cancer (ABC) who received no prior therapy for advanced disease

Geburtshilfe und Frauenheilkunde ◽

10.1055/s-0036-1592812 ◽

2016 ◽

Vol 76 (10) ◽

Author(s):

EM Grischke ◽

A Nusch ◽

N Marschner ◽

W Abenhardt ◽

J Wilke ◽

...

Keyword(s):

Breast Cancer ◽

Advanced Breast Cancer ◽

Postmenopausal Women ◽

Hormone Receptor ◽

Advanced Disease ◽

Advanced Breast ◽

Prior Therapy ◽

PALINA: A phase II safety study of palbociclib in combination with letrozole or fulvestrant in African American women with hormone receptor positive HER2 negative advanced breast cancer

Contemporary Clinical Trials Communications ◽

10.1016/j.conctc.2018.05.012 ◽

2018 ◽

Vol 10 ◽

pp. 190-192

Author(s):

Filipa Lynce ◽

Mervat Saleh ◽

Ayesha Shajahan-Haq ◽

Christopher Gallagher ◽

Asma Dilawari ◽

...

Keyword(s):

Breast Cancer ◽

African American ◽

Advanced Breast Cancer ◽

African American Women ◽

Phase Ii ◽

Hormone Receptor ◽

Advanced Breast ◽

Safety Study ◽

American Women ◽

Incidence and time course of everolimus-related adverse events in postmenopausal women with hormone receptor-positive advanced breast cancer: insights from BOLERO-2

Annals of Oncology ◽

10.1093/annonc/mdu009 ◽

2014 ◽

Vol 25 (4) ◽

pp. 808-815 ◽

Cited By ~ 87

Author(s):

H.S. Rugo ◽

K.I. Pritchard ◽

M. Gnant ◽

S. Noguchi ◽

M. Piccart ◽

...

Keyword(s):

Breast Cancer ◽

Adverse Events ◽

Advanced Breast Cancer ◽

Postmenopausal Women ◽

Hormone Receptor ◽

Time Course ◽

Advanced Breast ◽

Adverse Event Management of mTOR Inhibitors During Treatment of Hormone Receptor–Positive Advanced Breast Cancer: Considerations for Oncologists

Clinical Breast Cancer ◽

10.1016/j.clbc.2014.03.002 ◽

2014 ◽

Vol 14 (5) ◽

pp. 297-308 ◽

Cited By ~ 20

Author(s):

Denise A. Yardley

Keyword(s):

Breast Cancer ◽

Adverse Event ◽

Advanced Breast Cancer ◽

Hormone Receptor ◽

Mtor Inhibitors ◽

Advanced Breast ◽

Event Management ◽

Adverse Event Management

Current status of hormone therapy in patients with hormone receptor positive (HR+) advanced breast cancer

The Breast ◽

10.1016/j.breast.2014.09.006 ◽

2014 ◽

Vol 23 (6) ◽

pp. 710-720 ◽

Cited By ~ 24

Author(s):

Elsa Dalmau ◽

Alejandra Armengol-Alonso ◽

Montserrat Muñoz ◽

Miguel Ángel Seguí-Palmer

Keyword(s):

Breast Cancer ◽

Advanced Breast Cancer ◽

Hormone Therapy ◽

Hormone Receptor ◽

Advanced Breast ◽

Current Status ◽

The impact of mammalian target of rapamycin inhibition on bone health in postmenopausal women with hormone receptor-positive advanced breast cancer receiving everolimus plus exemestane in the phase IIIb 4EVER trial

Journal of Bone Oncology ◽

10.1016/j.jbo.2018.09.010 ◽

2019 ◽

Vol 14 ◽

pp. 100199 ◽

Cited By ~ 1

Author(s):

Peyman Hadji ◽

Oliver Stoetzer ◽

Thomas Decker ◽

Christian M. Kurbacher ◽

Frederik Marmé ◽

...

Keyword(s):

Breast Cancer ◽

Advanced Breast Cancer ◽

Postmenopausal Women ◽

Bone Health ◽

Hormone Receptor ◽

Mammalian Target Of Rapamycin ◽

Advanced Breast ◽

Phase Iiib ◽

The Impact